Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2012, Pages 171-180

  Furukawa, Takako ^a   Nakamori, Fumihiro ^a   Tetsuka, Kazuhiro ^a   Naritomi, Yoichi ^a   Moriguchi, Hiroyuki ^a   Yamano, Katsuhiro ^a   Terashita, Shigeyuki ^a   Teramura, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Glucuronidation; In vitro in vivo correlation; Intestinal metabolism; Quantitative prediction; UDP glucuronosyltransferase (UGT)

Indexed keywords

BUPRENORPHINE; DIAZEPAM; DICLOFENAC; DRUG METABOLITE; ENTACAPONE; EZETIMIBE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; KETOPROFEN; NARINGENIN; QUERCETIN; RALOXIFENE; RESVERATROL; TELMISARTAN; TOLCAPONE; TOLMETIN;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FUNCTION; INTESTINE METABOLISM; INTESTINE MICROSOME; MALE; MEMBRANE PERMEABILITY; METABOLIC CLEARANCE RATE; MICROSOME; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; RAT; TANDEM MASS SPECTROMETRY;

EID: 84860298606     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-088     Document Type: Article

References (43)

1. Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R. and Ball, S. E.: Drugdrug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 32: 1201-1208 (2004).
2. Ohno, S. and Nakajin, S.: Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptasepolymerase chain reaction. Drug Metab. Dispos., 37: 32-40 (2009).
3. Mizuma, T.: Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int. J. Pharm., 378: 140-141 (2009).
4. Kosoglou, T., Statkevich, P., Johnson-Levonas, A. O., Paolini, J. F., Bergman, A. J. and Alton, K. B.: Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet., 44: 467-494 (2005).
5. van Heek, M., Farley, C., Compton, D. S., Hoos, L., Alton, K. B., Sybertz, E. J. and Davis, H. R., Jr.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol., 129: 1748-1754 (2000).
6. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., Kusuhara, H., Ito, K. and Sugiyama, Y.: The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab. Pharmacokinet., 18: 365-372 (2003).
7. Kadono, K., Akabane, T., Tabata, K., Gato, K., Terashita, S. and Teramura, T.: Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab. Dispos., 38: 1230-1237 (2010).
8. Ritter, J. K.: Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics. Expert Opin. Drug Metab. Toxicol., 3: 93-107 (2007).
9. Kuhnle, G., Spencer, J. P., Chowrimootoo, G., Schroeter, H., Debnam, E. S., Srai, S. K., Rice-Evans, C. and Hahn, U.: Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun., 272: 212-217 (2000).
10. Mistry, M. and Houston, J. B.: Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab. Dispos., 15: 710-717 (1987).
11. FDA Drug Approval Package, Micards (Telmisartan) Tablets, Application No. 20850, 10 Nov. 1998, Pharmacology Reviews, pp. 32-51, http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20850_MICARDIS_pharmr_P1.pdf, http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20850_MICARDIS_pharmr_P2.pdf (accessed Nov. 2010).
12. Ebner, T., Heinzel, G., Prox, A., Beschke, K. and Wachsmuth, H.: Disposition and chemical stability of telmisartan 1-Oacylglucuronide. Drug Metab. Dispos., 27: 1143-1149 (1999).
13. Dalvie, D., Kang, P., Zientek, M., Xiang, C., Zhou, S. and Obach, R. S.: Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem. Res. Toxicol., 21: 2260-2271 (2008).
14. Lindstrom, T. D., Whitaker, N. G. and Whitaker, G. W.: Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica, 14: 841-847 (1984).
15. Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G. and van Breemen, R. B.: Human, rat, and mouse metabolism of resveratrol. Pharm. Res., 19: 1907-1914 (2002).
16. Brewster, D., Humphrey, M. J. and McLeavy, M. A.: Biliary excretion, metabolism and enterohepatic circulation of buprenorphine. Xenobiotica, 11: 189-196 (1981).
17. Chen, X., Yin, O. Q., Zuo, Z. and Chow, M. S.: Pharmacokinetics and modeling of quercetin and metabolites. Pharm. Res., 22: 892-901 (2005).
18. Palylyk-Colwell, E. L. and Jamali, F.: Effect of gonadectomy and hormones on sex differences in ketoprofen enantiomer glucuronidation and renal excretion of formed glucuronides in the rat. Pharm. Res., 21: 989-995 (2004).
19. FDA Drug Approval Package, Tasmar (Tolcapone) Tablets, Application No. 20697, 1 Jan. 1998, Pharmacology Reviews, p. 136, http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20697_Tasmar_pharmr_P3.pdf (accessed Nov. 2010).
20. Lave, T., Dupin, S., Schmitt, M., Kapps, M., Meyer, J., Morgenroth, B., Chou, R. C., Jaeck, D. and Coassolo, P.: Interspecies scaling of tolcapone, a new inhibitor of catechol-Omethyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica, 26: 839-851 (1996).
21. Wikberg, T., Vuorela, A., Ottoila, P. and Taskinen, J.: Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos., 21: 81-92 (1993).
22. Wikberg, T. and Vuorela, A.: Metabolite profiles of two [14C]- labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile. Eur. J. Drug Metab. Pharmacokinet., 19: 125-135 (1994).
23. Hoffman, D. J., Seifert, T., Borre, A. and Nellans, H. N.: Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm. Res., 12: 889-894 (1995).
24. Meng, X., Maliakal, P., Lu, H., Lee, M. J. and Yang, C. S.: Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem., 52: 935-942 (2004).
25. Lan, K., Jiang, X. and He, J.: Quantitative determination of isorhamnetin, quercetin and kaempferol in rat plasma by liquid chromatography with electrospray ionization tandem mass spectrometry and its application to the pharmacokinetic study of isorhamnetin. Rapid Commun. Mass Spectrom., 21: 112-120 (2007).
26. Sawada, Y.: Animal scale up. In Hanano M., Umemura, K. and Iga, T. (eds): Applied Pharmacokinetics-Theory and Experiments, Tokyo, Soft Science, Inc., 1985, p. 477.
27. Davies, B. and Morris, T.: Physiological parameters in laboratory animals and humans. Pharm. Res., 10: 1093-1095 (1993).
28. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A. and Sugiyama, Y.: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos., 29: 1316-1324 (2001).
29. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn., 4: 879-885 (1981).
30. Kemp, D. C., Fan, P. W. and Stevens, J. C.: Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos., 30: 694-700 (2002).
31. Jeong, E. J., Liu, Y., Lin, H. and Hu, M.: Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab. Dispos., 33: 785-794 (2005).
32. Shelby, M. K., Cherrington, N. J., Vansell, N. R. and Klaassen, C. D.: Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab. Dispos., 31: 326-333 (2003).
33. Nishimura, M., Koeda, A., Morikawa, H., Satoh, T., Narimatsu, S. and Naito, S.: Tissue-specific mRNA expression profiles of drugmetabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab. Pharmacokinet., 24: 139-144 (2009).
34. Buckley, D. B. and Klaassen, C. D.: Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab. Dispos., 35: 121-127 (2007).
35. Zhang, L., Zuo, Z. and Lin, G.: Intestinal and hepatic glucuronidation of flavonoids. Mol. Pharm., 4: 833-845 (2007).
36. Maiti, S. and Chen, G.: Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine. Drug Metab. Dispos., 31: 637-644 (2003).
37. Huang, C., Chen, Y., Zhou, T. and Chen, G.: Sulfation of dietary flavonoids by human sulfotransferases. Xenobiotica, 39: 312-322 (2009).
38. Mizuma, T., Kawashima, K., Sakai, S., Sakaguchi, S. and Hayashi, M.: Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans. J. Pharm. Sci., 94: 571-575 (2005).
39. Shimasaki, M., Yamashita, K., Imanishi, R., Yokoyama, K., Kuritani, M., Oiwa, Y. and Igarashi, T.: Pharmacokinetics of 14C-telmisartan (1): absorption, distribution and protein binding of 14C-telmisartan after a single oral administration to rats. Xenobio. Metabol. Dispos., 14: 425-431 (1999).
40. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J. P. and Ducharme, M. P.: Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther., 302: 369-373 (2002).
41. FDA Drug Approval Package, Comtan (Entacapone) Tablets, Application No. 20796, 30 Dec. 1999, Pharmacology Reviews, p. 90, http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20796_Comtan_pharmr_P1.pdf (accessed Nov. 2010).
42. Wenzel, E. and Somoza, V.: Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res., 49: 472-481 (2005).
43. FDA Drug Approval Package, Zetia (Ezetimibe) Tablets, Application No. 21445, 25 Oct. 2002, Pharmacology Reviews, p. 62, http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21445_Zetia_pharmr_P2.pdf (accessed Nov. 2010).